Implementation of a large liquid biopsy genomic profiling assay in a decentralized setting - Takeaway - MDSpire
From the Journals

Implementation of a large liquid biopsy genomic profiling assay in a decentralized setting

In this webinar, Dr. Gang Zheng MD, PhD, will share experience from the Mayo Clinic laboratory, how the lab approaches liquid biopsy and recent implementation data of a liquid biopsy assay to enable comprehensive genomic profiling (CGP).

  • April 30, 2026

Share

  • 1

    Overview of large panel liquid biopsy assays.

  • 2

    Advantages include lower cost and shorter turnaround times.

  • 3

    The TSO 500 ctDNA v2 assay includes blood and CSF inputs.

  • 4

    Performance metrics reviewed in a clinical setting.

  • 5

    Implementation data from Mayo Clinic laboratory shared.

  • 6

    Educational focus on ensuring variant reporting accuracy.

  • 7

    Assay not for diagnostic procedures, research use only.

Original Source(s)

Implementation of a large liquid biopsy genomic profiling assay in a decentralized setting

  • April 30, 2026

Related Content

Neoadjuvant/Adjuvant Doublet Significantly Improved Survival in Patients With Muscle-Invasive Bladder Cancer

The combination of the NECTIN4-directed antibody drug conjugate enfortumab vedotin-ejfv and the immunotherapy drug pembrolizumab is the established first-line standard-of-care treatment for patients w...

Trends and Challenges in Nitrosamine Testing Part Four The Regulatory Landscape

Following part two, which explored the analytical challenges involved in nitrosamine testing, our experts return to offer their top tips for building a method from scratch

  • April 17, 2026

  • 6 min
Is Standard of Care Optimal for the Individual Patient?

I am writing this from the hospital waiting room. My father is undergoing an 11-hour surgery to remove his parotid gland and a squamous cell carcinoma that has metastasized from his cheek and invaded ...